Eikon Therapeutics (EIKN)
Develops oncology therapies using live-cell single-molecule tracking and in-licensed clinical assets.
$11.38
At close+0.50 (+4.60%)
Something off on this page? Send us feedback.
Next report
Nov 12, 2026
estimated · in 70 days
EPS estimate
−$1.64
Revenue estimate
—
Fiscal quarter
Q3 FY26
EPSReportedEstimate
————Mar '26May '26Aug '26Nov '26
Reported————−$27.00−$2.46−$1.63Pending
Estimate————−$3.56−$1.98−$1.58−$1.64
Surprise————−658.4%−24.4%−3.2%—
RevenueReportedEstimate
————Mar '26May '26Aug '26Nov '26
Reported———————Pending
Estimate————————
Surprise————————
History
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| Nov 2026 | −$1.64 | — | — |
| Aug 2026 | −$1.58 | −$1.63 | −3.2% |
| May 2026 | −$1.98 | −$2.46 | −24.4% |
| Mar 2026 | −$3.56 | −$27.00 | −658.4% |
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Nov 12, 2026 | −$1.64 | — | — | — | — | — | — |
| Aug 13, 2026 | −$1.58 | −$1.63 | −3.2% | — | — | — | +7.0% |
| May 11, 2026 | −$1.98 | −$2.46 | −24.4% | — | — | — | +15.9% |
| Mar 30, 2026 | −$3.56 | −$27.00 | −658.4% | — | — | — | +9.3% |